From Questioning Answers.
B-cell depletion using several infusions of rituximab over 12 months was not associated with clinical improvement in patients with ME/CFS [Myalgic Encephalomyelitis/Chronic Fatigue Syndrome].”
That was the conclusion reached in the paper by Øystein Fluge and colleagues . Their findings based on the use of rituximab, “a drug that is often used to treat inflammatory diseases (for example, rheumatoid arthritis) and lymphoma” were not entirely unexpected (see here) as a familiar theme of small scale results  being ‘positive’ but not translating into gains during more methodologically-sound study was rehashed.
To read the rest of this story, click on the link below: